Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1478242/000147824221000020/iqv-20201231.htm
April 2024
February 2024
November 2023
November 2023
November 2023
September 2023
August 2023
May 2023
May 2023
April 2023
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--February 10, 2021--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended December 31, 2020.
Fourth-Quarter 2020 Operating Results
Revenue for the fourth quarter of $3,298 million increased 13.9 percent on a reported basis and 12.2 percent at constant currency, compared to the fourth quarter of 2019. Technology & Analytics Solutions (TAS) revenue of $1,425
million grew 17.4 percent on a reported basis and 15.1 percent at constant currency. Research & Development Solutions (R&DS) revenue of $1,684 million grew 14.5 percent on a reported basis and 13.2 percent at constant currency.
Excluding the impact of pass throughs, R&DS revenue increased 12.3 percent year-over-year on a reported basis. Contract Sales & Medical Solutions (CSMS) revenue of $189 million was lower by 10.0 percent on a reported basis and by
11.9 percent at constant currency.
R&DS contracted backlog, including reimbursed expenses, grew 18.5 percent year-over-year to $22.6 billion at December 31, 2020. The company expects approximately $5.9 billion of this backlog to convert to revenue in the next twelve months, representing growth of 13.5 percent compared to December 31, 2019. The fourth quarter contracted net book-to-bill ratio was 1.41x including reimbursed expenses and 1.42x excluding reimbursed expenses. For the year ended December 31, 2020, the contracted net book-to-bill ratio was 1.53x including reimbursed expenses and 1.44x excluding reimbursed expenses.
Fourth-quarter 2020 Adjusted EBITDA was $735 million, up 14.5 percent compared to the fourth quarter of 2019. GAAP net income was $119 million, and GAAP diluted earnings per share was $0.61. Adjusted Net Income was $411 million and Adjusted Diluted Earnings per Share was $2.11, up 21.3 percent compared to the fourth quarter of 2019.
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1478242/000147824221000020/iqv-20201231.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Iqvia Holdings Inc..
Iqvia Holdings Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:
Rating
Learn More
Costs of revenue include compensation and benefits for billable employees and personnel involved in production, trial monitoring, data management and delivery, and the costs of acquiring and processing data for our information offerings; costs of staff directly involved with delivering technology-related services offerings and engagements, related accommodations and the costs of data purchased specifically for technology services engagements; and other expenses directly related to service contracts such as courier fees, laboratory supplies, professional services and travel expenses.
Costs of Revenue, exclusive of Depreciation and Amortization 2020 compared to 2019 Contract Sales & Medical Solutions' costs of revenue, exclusive of depreciation and amortization, decreased $75 million, or 10.7%, in 2020 as compared to 2019.
In the event that a client cancels a contract, we typically would be entitled to receive payment for all services performed up to the cancellation date and subsequent client-authorized services related to winding down the canceled project.
The repatriation of cash balances from certain of our subsidiaries could have adverse tax consequences; however, those balances are generally available without legal restrictions to fund ordinary business operations.
This decrease was comprised of a constant currency revenue decline of approximately $75 million, or 9.2%, reflecting a volume decrease in the Americas region.
Cash Flow from Investing Activities...Read more
Cash Flow from Financing Activities...Read more
Years ended December 31, 2020,...Read more
Equity Repurchase Program On February...Read more
We regularly evaluate our debt...Read more
We also believe that the...Read more
This decrease was comprised of...Read more
The revenue growth in these...Read more
In order to measure benefit...Read more
We had a cash balance...Read more
Foreign Currency Translation In 2020,...Read more
Our insights and execution capabilities...Read more
We may use our existing...Read more
Selling, general and administrative expenses...Read more
We have determined we will...Read more
Technology & Analytics Solutions Revenues...Read more
Accordingly, exchange rate fluctuations will...Read more
Based on our current operating...Read more
Progress on the performance obligation...Read more
In instances where sites remain...Read more
Revenues 2020 compared to 2019...Read more
Income Tax Expense (Benefit) In...Read more
The revolving credit facility is...Read more
(4) Amounts represent expected future...Read more
Costs included in the measure...Read more
Senior Secured Credit Facilities and...Read more
Recording such an adjustment could...Read more
We cannot provide assurances that...Read more
Selling, General and Administrative Expenses...Read more
Costs and Expenses Our costs...Read more
At December 31, 2020, the...Read more
This increase was comprised of...Read more
We continue to see gradual...Read more
(2) Purchase obligations are defined...Read more
Due to the potential impact...Read more
As of December 31, 2020,...Read more
Additional information regarding the Repurchase...Read more
We have activated business continuity...Read more
We review the carrying values...Read more
This increase was comprised of...Read more
We have and expect to...Read more
Selling, General and Administrative Expenses...Read more
Selling, General and Administrative Expenses...Read more
We are managed through three...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Material Contracts, Statements, Certifications & more
Iqvia Holdings Inc. provided additional information to their SEC Filing as exhibits
Ticker: IQV
CIK: 1478242
Form Type: 10-K Annual Report
Accession Number: 0001478242-21-000020
Submitted to the SEC: Fri Feb 12 2021 4:16:25 PM EST
Accepted by the SEC: Fri Feb 12 2021
Period: Thursday, December 31, 2020
Industry: Commercial Physical And Biological Research